Point-of-care deal pairs Meredith content with Mesmerize network by Beth Snyder Bulik Thursday, February 7, 2019 Content is king, and it’s especially important in pharma. That’s why point-of-care agency Mesmerize has inked a deal with a top magazine publisher.
PBMs cast themselves as drug cost cutters in new digital ads by Beth Snyder Bulik Wednesday, February 6, 2019 As the Trump administration weighs ending rebates to PBMs, their trade group has debuted ads asserting the cost-cutting value of the industry middlemen.
Test run of drug prices in ads exposes a workaround for pharma by Beth Snyder Bulik Wednesday, January 30, 2019 The Trump proposal requiring pharma companies to add drug prices to advertising might not work according to plan.
Allergan taps Real Housewife for latest CoolSculpting promo by Beth Snyder Bulik Monday, January 28, 2019 Allergan partners with a Real Housewives celebrity in its latest promotion for fat-freezing treatment CoolSculpting.
McCann Health names new chief creative officer by Beth Snyder Bulik Monday, January 7, 2019 Matt Eastwood, McCann Health’s new global chief creative officer, fills a role that's been vacant since July.
Humira, Xeljanz top pharma TV spend in Dec. by Beth Snyder Bulik Thursday, January 3, 2019 Could Pfizer's Xeljanz become the 2019 challenger to AbbVie’s Humira TV ad crown?
Expect more transparency around advocacy partnerships in 2019 by Beth Snyder Bulik Wednesday, December 19, 2018 Advocacy groups and pharma companies often work hand in hand, but this year saw some of the shine wear off.
Lions Health taps jury heads for health & wellness, pharma awards by Beth Snyder Bulik Monday, December 10, 2018 Cannes Lions Health last week named the two jury chiefs set to oversee advertising awards in health & wellness and pharma.
Seniors want to see drug prices in ads: survey by Beth Snyder Bulik Wednesday, November 14, 2018 Who wants drug prices in ads? Older people, that’s who.
Azar deals woe to DTC—and Big Pharma—with ad-pricing proposal by Beth Snyder Bulik Tuesday, October 16, 2018 Pharma might have thought it could fend off the Trump administration's bid to get drug prices into consumer advertising, but it was wrong.
